Medpace (MEDP) Ascends While Market Falls: Some Facts to Note

Medpace (MEDP) closed the most recent trading day at $543.57, moving +2.64% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.22%. At the same time, the Dow lost 0.03%, and the tech-heavy Nasdaq lost 0.66%. Shares of the provider of outsourced clinical development services witnessed a gain of 18.85% over the previous month, beating the performance of the Medical sector with its gain of 6.47%, and the S&P 500's loss of 1.21%.Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on July 22, 2026. In that report, analysts expect Medpace to post earnings of $4.08 per share. This would mark year-over-year growth of 31.61%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $678.51 million, up 12.47% from the year-ago period. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.04 per share and revenue of $2.79 billion, indicating changes of +11.52% and +10.32%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for Medpace. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. At present, Medpace boasts a Zacks Rank of #3 (Hold). Investors should also note Medpace's current valuation metrics, including its Forward P/E ratio of 31.08. This denotes a premium relative to the industry average Forward P/E of 15.95. Also, we should mention that MEDP has a PEG ratio of 2.69. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical Services industry was having an average PEG ratio of 1.39. The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks